Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CEL-SCI Co. stock logo
CVM
CEL-SCI
$2.43
-1.2%
$5.08
$1.98
$66.60
$7.37M0.2775,875 shs129,134 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.19
+2.6%
$0.99
$0.81
$1.76
$27.43M0.74128,666 shs237,872 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.40
+2.1%
$3.19
$2.57
$6.88
$20.58M0.639,047 shs4,810 shs
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$2.35
+9.3%
$2.51
$1.41
$35.99
$3.17M2.88574,340 shs71,630 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CEL-SCI Co. stock logo
CVM
CEL-SCI
-1.22%+4.74%-3.19%-66.25%-93.36%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
+2.59%+15.53%+22.05%+13.33%-15.60%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
+2.10%-0.58%+1.49%-2.86%-47.04%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
+9.30%+13.53%+16.92%+25.00%+67.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.0654 of 5 stars
0.02.00.00.00.00.00.6
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.0718 of 5 stars
3.75.00.00.00.00.80.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.3848 of 5 stars
0.03.00.00.00.01.70.6
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
3.1766 of 5 stars
3.35.00.00.00.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00
N/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.33
Buy$10.00740.34% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
2.50
Moderate Buy$7.00197.87% Upside

Current Analyst Ratings Breakdown

Latest SXTP, CVM, ENLV, and NAII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
6/2/2025
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.80 ➝ $7.00
5/24/2025
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
5/10/2025
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
4/24/2025
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
4/21/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/8/2025
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (E+)
4/3/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/28/2025
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.15 per shareN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$1.00 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.18N/AN/A$13.32 per share0.26
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$300K11.52N/AN/A($6.38) per share-0.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-$7.95M-$50.41N/AN/AN/A-1,947.30%N/A-174.90%8/13/2025 (Estimated)

Latest SXTP, CVM, ENLV, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.15+$0.01-$0.15N/AN/A
5/15/2025Q1 2025
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-$1.31-$1.56-$0.25-$1.56$0.15 million$0.18 million
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
3/31/2025Q4 2024
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.23-$0.07-$0.23N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.66
1.07
1.09
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
7.20
7.20
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
N/A
3.14
2.71

Institutional Ownership

CompanyInstitutional Ownership
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
7.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
433.03 million64.67 millionOptionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7023.65 million20.75 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
31.47 million1.32 millionNot Optionable

Recent News About These Companies

60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals announces 1-for-5 reverse stock split
60 Degrees says FDA does not object to tafenoquine import plan

New MarketBeat Followers Over Time

Media Sentiment Over Time

CEL-SCI stock logo

CEL-SCI NYSE:CVM

$2.43 -0.03 (-1.22%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$2.44 +0.01 (+0.62%)
As of 06/24/2025 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.19 +0.03 (+2.59%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$1.19 0.00 (0.00%)
As of 06/24/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.38 +0.05 (+1.50%)
As of 06/24/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTP

$2.35 +0.20 (+9.30%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$2.29 -0.06 (-2.72%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.